Takeda Pharmaceutical Co. has decided to terminate development of fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. The company has worked with three independent panels regarding safety oversight, including the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program.
 
Following a review of the data emerging from all the clinical trials and in consultation with these panels, the company has decided that the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks, and has decided to voluntarily terminate development activities for fasiglifam.